<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <id>https://recalls.watch/feed/substance-dabigatran.xml</id>
  <title>Recalls Watch: Dabigatran</title>
  <link rel="self" href="https://recalls.watch/feed/substance-dabigatran.xml"/>
  <link href="https://recalls.watch/alerts/"/>
  <updated>2026-08-05T00:00:00Z</updated>
  <entry>
    <id>https://recalls.watch/recall/fda/99421/</id>
    <title>Ascend Laboratories, LLC: Dabigatran Etexilate Capsules and 2 more</title>
    <link href="https://recalls.watch/recall/fda/99421/"/>
    <updated>2026-08-05T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/99330/</id>
    <title>Ascend Laboratories, LLC: Dabigatran etexilate Capsules and 1 more</title>
    <link href="https://recalls.watch/recall/fda/99330/"/>
    <updated>2026-07-29T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/95896/</id>
    <title>Ascend Laboratories, LLC: Dabigatran Etexilate and 1 more</title>
    <link href="https://recalls.watch/recall/fda/95896/"/>
    <updated>2024-12-18T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/91880/</id>
    <title>Ascend Laboratories, LLC: Dabigatran Etexilate Capsules and 1 more</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=91880"/>
    <updated>2023-04-05T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.</summary>
  </entry>
</feed>
